Welcome to our dedicated page for Hologic news (Ticker: HOLX), a resource for investors and traders seeking the latest updates and insights on Hologic stock.
Hologic, Inc. (Nasdaq: HOLX) generates a steady flow of news centered on women’s health, medical technology innovation and corporate developments. As a company that describes itself as focused on developing technologies to detect, diagnose and treat health conditions, many of its announcements highlight advances in diagnostics, breast imaging, oncology testing and digital pathology.
Investors and healthcare professionals following HOLX news will find updates on Hologic’s diagnostic platforms, such as the Panther and Panther Fusion systems, including regulatory milestones like FDA clearance and CE marking for new assays. Recent communications have covered automated molecular tests for gastrointestinal bacterial pathogens, which expand the company’s infectious disease testing menu and illustrate its emphasis on rapid, molecular-based diagnostics.
Hologic’s news feed also features developments in breast health technologies. The company has publicized data on its AI-powered mammography tools, such as the Genius AI Detection solution and 3DQuorum imaging technology, through studies conducted at major medical centers and presented in peer-reviewed journals or at scientific meetings. These stories often focus on how artificial intelligence can support radiologists by flagging suspicious areas on mammograms and streamlining image review without compromising cancer detection performance.
Oncology and precision medicine are recurring themes. Hologic and its subsidiary Biotheranostics, Inc. issue updates about the Breast Cancer Index Test, including new clinical evidence presented at conferences like the San Antonio Breast Cancer Symposium. These releases describe how the test may inform extended endocrine therapy decisions for patients with early-stage, hormone receptor–positive breast cancer and examine its performance in various patient subgroups.
Beyond technology and clinical data, Hologic’s news includes educational initiatives and partnerships, such as the "Ultimate Defense" cervical cancer screening awareness campaign with professional basketball player Erica Wheeler, and collaborations in epigenomics and pharmaco-epigenetics through Hologic Diagenode and co-marketing agreements. Corporate and financial announcements, including quarterly earnings releases and the proposed acquisition of Hologic by funds managed by Blackstone and TPG, provide additional context for HOLX stockholders.
For readers interested in HOLX news, this page offers a centralized view of Hologic’s product milestones, clinical research, public health campaigns and transaction-related updates, making it a useful resource for tracking how the company’s activities evolve over time.
Hologic, Inc. (Nasdaq: HOLX) will announce its Q2 fiscal 2021 financial results on April 28 after market close. A conference call hosted by management will take place at 4:30 p.m. ET the same day. Interested listeners can join the call by dialing the provided numbers or by clicking a link. A replay will be available until May 21. Hologic focuses on enhancing women's health through early detection and treatment technologies.
Summary not available.
Hologic, a leader in women's health, announced a collaboration with Gallup to create the Hologic Global Women’s Health Index, the most extensive assessment of women’s health globally. This survey will encompass over 120,000 responses across 116 countries and will track vital metrics related to women’s health, including reproductive health and access to care. The project aims to address healthcare disparities exacerbated by the COVID-19 pandemic and will provide insights for policy improvement. The index is set to be published later this year.
Hologic, Inc. (Nasdaq: HOLX) has acquired Diagenode, a European developer of molecular diagnostic assays, for approximately $159 million. This acquisition aims to enhance Hologic's molecular diagnostics capabilities, speeding up international market entry and expanding their test menu. Diagenode brings over 30 real-time PCR tests for various infections and significant expertise in epigenetics. The acquisition is expected to be break-even to Hologic's non-GAAP earnings per share through fiscal 2022, with potential for future accretion.
Hologic, Inc. (NASDAQ: HOLX) has successfully completed its acquisition of Biotheranostics, a leader in molecular oncology, for approximately $230 million. Biotheranostics specializes in molecular diagnostic tests such as the Breast Cancer Index and CancerTYPE ID, which aid in predicting treatment benefits and optimizing therapy for patients with uncertain cancers. Following the acquisition, Hologic aims to grow in the expanding oncology market, leveraging the National Comprehensive Cancer Network's recent endorsement of Breast Cancer Index as a key predictive tool for hormone-receptor positive breast cancer.
A recent study published in the Journal of the American College of Radiology highlights significant racial disparities in breast cancer screening, particularly in digital breast tomosynthesis (DBT). The research, commissioned by Hologic (HOLX), analyzed data from over 385,000 women across various racial backgrounds and found that Black women were less likely to receive DBT mammograms, despite their higher mortality rate from breast cancer. Hologic is dedicated to addressing these disparities through partnerships and initiatives aimed at increasing access to advanced screening technologies for Black women.
AMETEK announced the appointment of Karleen Oberton to its Board of Directors, effective February 11, 2021. Oberton currently serves as CFO of Hologic and has over 30 years of experience in public accounting, biotechnology, and medical device manufacturing. Her expertise in finance and executive leadership is expected to enhance AMETEK's board dynamics. The company reported 2020 sales exceeding $4.5 billion and aims for double-digit growth in earnings per share over the business cycle.
Hologic, Inc. (Nasdaq: HOLX) will present at several upcoming virtual investor conferences, highlighting its commitment to women's health technology. Key events include:
- BTIG Virtual MedTech Conference on February 17 at 10:30 a.m. ET
- Citi’s Healthcare Services Conference on February 24 at 11:40 a.m. ET
- SVB Leerink’s Global Healthcare Conference on February 25 at 1:00 p.m. ET
- Raymond James Institutional Investors Conference on March 1 at 1:20 p.m. ET
All presentations will be webcast live and accessible on Hologic's investor website.
Summary not available.
Hologic, Inc. (HOLX) has entered into a multi-year strategic collaboration with Google Cloud to integrate machine learning technologies with its Genius™ Digital Diagnostics System. This partnership aims to enhance cervical cancer screening by using AI for improved identification of pre-cancerous lesions and cancer cells. Hologic's President emphasized this as a natural progression in their 30-year commitment to cervical cancer screening. While the Genius system is CE-marked for the European market, it is not yet available in the U.S. Financial terms of the collaboration were not disclosed.
FAQ
What is the current stock price of Hologic (HOLX)?
What is the market cap of Hologic (HOLX)?
